SBS3 is observed in breast, pancreatic, and ovarian cancers, and was related to somatic and germline BRCA1/2 mutations as well as defective homologous recombination (HR) base repair (Alexandrov et al. 2020). This evidence concerns the gene BRCA1 and ovarian cancer.